Cosentyx® (secukinumab) case studies: a decade of real-world clinical experience^1,2

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adults (alone or in combination with methotrexate [MTX]) who have responded inadequately to disease-modifying anti-rheumatic drug therapy.³

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.

Case study videos on demand

A decade of innovation with IL-17A

Watch our latest recording featuring Dr Gurdeep Dulay , as he discusses one of his long-term patients with PsA, exploring treatment failure with a TNFi and how treatment decision can support eligible PsA patients to achieve remission.

A decade of ... Looking to the future

Watch our latest recording featuring Professor Philip Conaghan as he takes us through one of his long-term patients with PsA, exploring key data and treatment decisions over the years.

Choose Cosentyx for your eligible patients, an IL-17A inhibitor with over a decade of experience and a consistent safety profile across indications^1–3

The most frequently reported adverse reactions are upper respiratory tract infections (17.1%) (most frequently nasopharyngitis, rhinitis). Caution should be exercised when considering the use of Cosentyx in patients with a chronic infection or a history of recurrent infection. If a patient develops a serious infection, the patient should be closely monitored and Cosentyx should not be administered until the infection resolves. Patients should be evaluated for tuberculosis infection prior to initiating treatment with Cosentyx. Cosentyx should not be given to patients with active tuberculosis. In patients with latent tuberculosis, anti‑tuberculosis therapy should be considered prior to initiation of Cosentyx. Cosentyx is not recommended in patients with IBD. If a patient develops signs and symptoms of IBD or experiences an exacerbation of pre-existing inflammatory bowel disease, Cosentyx should be discontinued and appropriate medical management should be initiated.¹

Please refer to the SmPC for full safety information before prescribing.

*Since first indication in 2015 for eligible adults with moderate to severe PsO.¹

Therapeutic Indications³
Cosentyx is indicated for the treatment of moderate to severe PsO in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active PsA in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe HS (acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.³

AS, ankylosing spondylitis; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; IL-17, interleukin 17A; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, psoriasis; SmPC, summary of product characteristics; TNFi, tumor necrosis factor inhibitor.

References

1. European Medicines Agency. Summary of positive opinion. EMA/CHMP/670627/2015. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx_en.pdf [Accessed October 2025]. 

2. European Medicines Agency. Assessment report: Cosentyx. EMA/CHMP/389874/2014. Available at: https://www.ema.europa.eu/en/documents/assessment-report/cosentyx-epar-public-assessment-report_en.pdf [Accessed October 2025]. 

3. Cosentyx® (secukinumab) Summary of Product Characteristics.

4. ClinicalTrials.gov. Secukinumab search results. Available at: https://www.clinicaltrials.gov/search?term=Secukinumab&aggFilters=status:com%20rec%20act [Accessed October 2025]. 

5. Novartis Data on File. Secukinumab (SEC018). February 2025.

UK | October 2025 | FA-11463462-2